CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL

NCT00586391 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

14

Enrollment

OTHER

Sponsor class

Conditions

B Cell Lymphoma
Chronic Lymphocytic Leukemia
Acute Lymphocytic Leukemia

Interventions

GENETIC: CD19CAR-28-zeta T cells
DRUG: Ipilimumab

Sponsor

Baylor College of Medicine

Collaborators

[object Object]
[object Object]